Canada Life’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Canada Life's KYMR Position: Q3 2026 in Review
Canada Life increased its Kymera Therapeutics (KYMR) stake by 9.6% in Q3 2026, buying an estimated $58.2K and bringing the position to 5,818 shares worth $649K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.
Canada Life first reported a position in KYMR in Q4 2020 and has held it in 24 quarters since. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Canada Life held 5,818 shares of Kymera Therapeutics worth $649K as of Q3 2026.
- Canada Life bought 508 Kymera Therapeutics shares in Q3 2026, an estimated $58.2K.
- Kymera Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q3 2026, its #1433 holding.
- Canada Life first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 24 quarters since.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Canada Life's 13F filing for Q3 2026, filed 13 Nov 2026.